Clinical Trials
7 trialsNCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
NCT03651206 2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3 Recruiting
NCT05515575 2025-10-20
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05174455 2023-09-18
Niraparib for the Treatment of Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02044120 2021-01-12
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
Sarcoma Alliance for Research through Collaboration
Phase 1 Completed